TH168550A - Liquid formulation containing GM-CSF neutralizing compounds. - Google Patents
Liquid formulation containing GM-CSF neutralizing compounds.Info
- Publication number
- TH168550A TH168550A TH1501002337A TH1501002337A TH168550A TH 168550 A TH168550 A TH 168550A TH 1501002337 A TH1501002337 A TH 1501002337A TH 1501002337 A TH1501002337 A TH 1501002337A TH 168550 A TH168550 A TH 168550A
- Authority
- TH
- Thailand
- Prior art keywords
- csf
- negates
- disorders
- compound
- tonic
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 7
- 239000000203 mixture Substances 0.000 title claims abstract 7
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 title claims abstract 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 title claims abstract 6
- 238000009472 formulation Methods 0.000 title claims abstract 5
- 239000007788 liquid Substances 0.000 title 1
- 230000003472 neutralizing Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 claims abstract 6
- 230000000694 effects Effects 0.000 claims abstract 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract 4
- 239000003607 modifier Substances 0.000 claims abstract 4
- 230000001256 tonic Effects 0.000 claims abstract 4
- 208000006673 Asthma Diseases 0.000 claims abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract 2
- 201000005794 allergic hypersensitivity disease Diseases 0.000 claims abstract 2
- 230000002567 autonomic Effects 0.000 claims abstract 2
- 230000002757 inflammatory Effects 0.000 claims abstract 2
- 239000004615 ingredient Substances 0.000 claims abstract 2
- 201000004681 psoriasis Diseases 0.000 claims abstract 2
- 230000001225 therapeutic Effects 0.000 claims abstract 2
- 206010003246 Arthritis Diseases 0.000 claims 1
- 230000002917 arthritic Effects 0.000 abstract 1
Abstract
คำขอใหม่ปรับปรุงวันที่ 15/02/2559 การประดิษฐ์นี้เกี่ยวข้องกับสูตรผสมเอเควียสซึ่งประกอบรวมด้วยสารประกอบซึ่งลบล้าง ฤทธิ์ GM-CSF ในความเข้มข้นอย่างน้อยประมาณ 20 mg/ml, ตัวดัดแปลงสภาพโทนิกและบัฟเฟอร์ โดยที่องค์ประกอบเสถียร ส่วนผสมของสูตรผสมที่ควรใช้คือให้ความเสถียรแก่สารประกอบซึ่ง ลบล้างฤทธิ์ GM-CSF เมื่อเก็บรักษาในระยะยาว ในลักษณะที่ควรใช้สูตรผสมคือสำหรับการใช้ การบำบัด ที่ควรใช้คือสำหรับการใช้ในการรักษาความผิดปกติทางการอักเสบและออโตอิมมูน ที่ควรใช้คือที่รวมถึงความผิดปกติทางภูมิแพ้และสะเก็ดเงิน เช่นเดียวกับความผิดปกติทางข้ออักเสบ และหอบหืด นอกจากนี้ชุดอุปกรณ์ซึ่งประกอบรวมด้วยสูตรผสมของการประดิษฐ์ถูกให้ไว้ด้วย New Request, Revised 15/02/2016 This invention relates to the AKVI-based formulation consisting of a compound that negates the GM-CSF activity in a concentration of at least 20 mg / ml, a tonic modifier. And buffer Where the component is stable The preferred formulation ingredient is to stabilize the compound, which negates the effect of GM-CSF over long term storage. The manner in which the formula should be used is for therapeutic use, that is, for the treatment of inflammatory and autonomic disorders. They should be used including allergy and psoriasis disorders. As well as for arthritic and asthma disorders. Additionally, a kit consisting of an invention formula is provided.
Claims (1)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TH168550A true TH168550A (en) | 2017-09-28 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20190045A7 (en) | COMPOUNDS DERIVED FROM 1,2,4-TRIAZOLONES 2,4,5-TRISUSTITUIDES WHICH ARE INHIBITORS OF DIHYDROOROTATE DEHYDROGENASE (DHODH), USEFUL FOR THE TREATMENT OR PREVENTION OF HYPERPROLIFERATIVE AND INFLAMMATORY DISORDERS | |
| BR112015029970A2 (en) | kinase inhibitors | |
| EA201591727A1 (en) | BIARYLAMIDE COMPOUNDS AS KINASE INHIBITORS | |
| EA201891120A1 (en) | 1,3-TIAZOL-2-IL-SUBSTITUTED BENZAMIDES | |
| BR112015014034A2 (en) | irak inhibitors and uses thereof | |
| BR112015020302A2 (en) | pyrazole derivative | |
| BR112014026703A2 (en) | dna-pk inhibitors | |
| EA201690598A1 (en) | AMINOGETEROARIL BENZAMIDES AS KINASE INHIBITORS | |
| BR112016009889A2 (en) | gip-glp-1 double agonist compounds and methods | |
| EA200870216A1 (en) | AMIDO COMPOUNDS AND THEIR APPLICATION AS MEDICINES | |
| MX355330B (en) | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS and USES THEREOF. | |
| PH12016502100A1 (en) | Liquid formulation comprising gm-csf neutralizing compound | |
| BR112015019412A2 (en) | bace1 inhibitors | |
| PH12015500864A1 (en) | Liquid formulation comprising gm-csf neutralizing compound | |
| CA2929436C (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
| UA117032C2 (en) | A selective inhibitor of phosphatidylinositol 3-kinase-gamma | |
| BR112014005538A2 (en) | aqueous compositions comprising arbecacin | |
| WO2014108337A8 (en) | Pyrazolyl-based carboxamides i as crac channel inhibitors | |
| EA201591653A1 (en) | COMPOSITIONS FOR THE TREATMENT OF EYE DISORDERS USING DIPYRIDAMOL | |
| EA201591180A1 (en) | COMPOSITIONS OF THE LFA-1 INHIBITOR | |
| EA201790072A1 (en) | DERIVATIVES 2-ARYL-4-HYDROXY-1,3-TIAZOLE FOR USE AS TRPM8 INHIBITORS IN THE TREATMENT OF NEURALGIA, PAIN, CHRONIC OBSTRUCTIVE LUNG AND ASTHMA | |
| WO2014108336A8 (en) | Pyrazolyl-based carboxamides ii as crac channel inhibitors | |
| BR112015019524A2 (en) | combination treatment | |
| TH168550A (en) | Liquid formulation containing GM-CSF neutralizing compounds. | |
| BR112015005876A2 (en) | low melting propionic acid derived particles for use in oral dosage forms |